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Pharmacogenomic and clinical data link
non-pharmacokinetic metabolic dysregulation
to drug side effect pathogenesis
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Markus J. Herrgard1,6, Monica L. Mo1,w & Bernhard O. Palsson1,7
Drug side effects cause a signiﬁcant clinical and economic burden. However, mechanisms of
drug action underlying side effect pathogenesis remain largely unknown. Here, we integrate
pharmacogenomic and clinical data with a human metabolic network and ﬁnd that
non-pharmacokinetic metabolic pathways dysregulated by drugs are linked to the
development of side effects. We show such dysregulated metabolic pathways contain
genes with sequence variants affecting side effect incidence, play established roles in
pathophysiology, have signiﬁcantly altered activity in corresponding diseases, are susceptible
to metabolic inhibitors and are effective targets for therapeutic nutrient supplementation. Our
results indicate that metabolic dysregulation represents a common mechanism underlying
side effect pathogenesis that is distinct from the role of metabolism in drug clearance. We
suggest that elucidating the relationships between the cellular response to drugs, genetic
variation of patients and cell metabolism may help managing side effects by personalizing
drug prescriptions and nutritional intervention strategies.
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A
dverse drug reactions, commonly known as side effects,
are thought to be responsible for as much as 11% of
hospital admissions1,2, a ﬁfth of both phase II3 and III4
clinical trial failures, high-proﬁle market withdrawals
(for example, Vioxx, Lipobay), and a large fraction of patient
therapeutic non-compliance incidents5. Risk factors associated
with side effects have been identiﬁed, including number of drugs
prescribed6, patient age7 and genetic variants8. Side effect-linked
genetic variants identiﬁed so far are predominantly associated
with drug pharmacokinetics, thereby affecting exposure of the
body to a particular drug, but these variants do not give
any indication of the mechanism by which pathogenesis is
initiated. A recent study suggests that as many as half of drug side
effects are related to known drug–protein-binding events9,
and progress has been made towards systematically identifying
drug-binding events10. However, only modest progress has
been made towards elucidating speciﬁc drug-induced changes
downstream of binding events for the majority of drugs
(Fig. 1a)11. These downstream effects in many cases may be
most directly tied to side effect pathogenesis as well as patient
genetic and environmental background.
Recent literature suggests that altered gene expression induced
by drug treatment may be one mechanism by which drugs induce
systemic off-target effects12–15. Unfortunately, the lack of clinical
data has impeded the determination of causality of particular
gene expression changes in side effect pathogenesis16. Recent
studies have successfully utilized in vitro drug-treated gene
expression proﬁles to predict clinical drug effectiveness17,18,
suggesting that in vitro data may contain features that are
clinically conserved. However, demonstrating the relevance of
in vitro drug response features to clinical side effect pathogenesis
presents a signiﬁcant challenge, due largely to the lack of suitable
validating data sets and difﬁculty of clinical experimentation.
To address this challenge, we develop a network-based data
analysis workﬂow built upon the use of in vitro drug treatment
data to identify candidate side effect-linked features and a large
collection of historical clinical and disease model data as a
source of validation (Fig. 1). First, we identify in vitro gene
expression changes preferentially induced by drugs with clinically
deﬁned side effects to identify candidate side effect-linked
expression features. Then, we cross-reference these side effect-
linked features with independent legacy clinical data found in the
literature to corroborate their relevance in terms of ﬁve causal
relationships. We implement this strategy within the context of
the reconstructed global human metabolic network19,20, which
provides a biologically coherent structure for data integration due
to the high degree of network annotation and clear functional
connectivity between genes via metabolic pathways20,21.
Results
Calculation of drug-induced metabolite perturbations. We ﬁrst
identiﬁed drug-induced metabolic gene expression changes
within 6,040 gene expression proﬁles in the Connectivity Map
(CMap) data set, representing three human cell lines exposed to
1,221 drug compounds22 (Fig. 1a). We analysed the expression
proﬁles using the reconstructed global human metabolic network
Recon 1 (ref. 19) with a novel metabolic pathway analysis
algorithm, termed MetChange (Metabolite-Centered Hotspots of
Altered Network Gene Expression). MetChange is a constraint-
based modelling23 algorithm that computes a score for each
metabolite summarizing the drug-induced gene expression
changes along calculated production pathways for the
metabolite (Fig. 2). A MetChange score for a metabolite deﬁnes
how expression has changed in a pathway containing these
metabolite production reactions. Production in this case does not
necessarily indicate secretion, as the majority of metabolites
produced by one metabolic pathway are consumed in other
metabolic pathways. We also note that gene expression is not the
sole determinant of pathway activity, as gene and protein
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Figure 1 | Overview and workﬂow used in this study. (a) Studies
examining side effect pathogenesis focus primarily on drug
pharmacokinetics, involving drug transport and clearance, and drug binding
in terms of on and off target-binding events. This study examines potential
pathogenic mechanisms related to transcriptional changes downstream of
clearance and binding events. (b) Drug-treated gene expression proﬁles from
the Connectivity Map database are analysed in the context of the metabolic
network reconstruction Recon 1 using constraint-based modelling to identify
drug-induced pathway expression changes. Drug-induced metabolic pathway
expression changes are analysed in terms of drug side effects from the Side
Effect Resource (SIDER) using a feature selection genetic algorithm to
determine metabolic pathway perturbations conserved in particular side
effects, termed DISLoDGED pathways. (c) A new database, the Metabolism
Disease Database (MDDB), was generated by manual curation of literature
to establish links between altered metabolic pathway function and
pathologies, and this database was used to analyse DISLoDGED metabolic
pathways. (d) Five candidate causal mechanisms for metabolic changes in
side effect pathogenesis (listed in the MDDB panel) are assessed in a large-
scale manner by comparing these in vitro perturbations to clinical data linking
particular metabolic pathways to disease.
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expression are imperfectly correlated and enzyme functional state
may change due to perturbation as well. However, change in
metabolic gene expression may still indicate a pathogenic
metabolic functional change.
Validation of calculated metabolic perturbations. To compare
the MetChange method against existing approaches that predict a
metabolic outcome based on gene expression data18,24, a
published gene expression data from carbon and nitrogen
starvation in S. cerevisiae was analysed25,26. A previously
generated metabolic reconstruction of S. cerevisiae, iMM904
(ref. 27), was used to compute MetChange scores for each
condition. Scores were compared with metabolomics data
generated for the same conditions using the relative changes
from the initial time point. A total of 60 metabolites across ﬁve
time points for each carbon and nitrogen starvation were
compared for both absolute (that is, magnitude) correlation and
directional (that is, increased or decreased) correlation with
MetChange scores. The MetChange algorithm compared
favourably both with other network-based expression analysis
methods and with the use of gene expression alone in predicting
metabolic perturbations (Fig. 3). Reassuringly, k-means clustering
and principle component analysis of MetChange scores, mapped
metabolomics data, and mapped expression data suggest that
MetChange scores maintain functional relationships between
time points that are present in expression and metabolomics data
(Fig. 3).
To further validate the metabolic perturbations predicted by
the MetChange method using the CMap data set, we performed
a number of high-throughput computational analyses comparing
MetChange perturbations with drug response properties
(Table 1). First, metabolite scores were compared with co-
occurrences of drug-metabolite text terms in the PubMed
database. A bootstrap analysis of Z-score permutations showed
that PubMed drug-metabolite associations are recalled in a
statistically signiﬁcant manner (non-parametric perturbation
P-value Po10 3 for 1,000 perturbations of MetChange scores).
Second, it was found that known metabolic drug targets as found
in the DrugBank database28,29 are signiﬁcantly closer in reaction
proximity to known highly perturbed metabolites than less
perturbed metabolites for these drugs (median Wilcoxon rank
sum Po1.65 10 10 for the highest scoring bin). Third,
MetChange scores were found to be able to predict drug–
protein literature co-associations within the PubMed database in
a statistically signiﬁcant manner (non-parametric perturbation
Po0.01).
Finally, we validated perturbation predictions in targeted
experimental measurements in MCF-7 cell culture under
treatment by the drugs metformin, haloperidol and genistein.
These drugs were chosen because of previous evidence suggesting
signiﬁcant metabolic perturbation by these drugs. Measured
metabolites were chosen to have broad coverage of pathways and
target highly perturbed pathways as predicted by MetChange.
Drug concentrations were chosen based on previous in vitro
studies using these drugs.
First, treatment with the antipsychotic haloperidol revealed
decreased uptake of vitamin B6, consistent with the calculated
decrease in the B6 processing pathway (Fig. 4a). Second,
treatment with metformin, a 50 AMP-activated protein kinase
(AMPK) activator, showed signiﬁcant perturbation of tricar-
boxylic acid cycle and fatty acid oxidation metabolites. The
observed change was consistent with the large calculated
perturbation but was in the opposite direction of the transcrip-
tional change, indicating substantial non-transcriptional control
of the metabolite levels (Fig. 4b). Additional calculated
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Figure 2 | Description of the MetChange algorithm. (1) Using a metabolic
network reconstruction, sink (demand) reactions are added for each
metabolite. Demand reactions are irreversible with the stoichiometry:
metabolite 4 Ø. Each demand reaction is maximized in turn to obtain
maximal production values for each metabolite using a linear programming
problem (LP Problem 1). (2) Reaction presence/absence P-values are
generated from gene expression data and mapped onto the metabolic
network. A second linear programming problem is then solved (LP
Problem 2) for each metabolite. LP Problem 2 identiﬁes the ﬂux solution
that minimizes the inconsistency of the gene expression data with the
optimal production of a metabolite by restricting the demand reaction for
the metabolite to be at maximal ﬂux, and subsequently minimizing an
inconsistency score of (v P-values). (3) An example case for metabolite 1.
It is observed that the control data have greater expression (lower
presence/absence P-value) for certain production reactions. Greater
expression of production reactions results in a lower production
inconsistency score for the control gene expression sample, compared with
the drug-treated case, in which certain production reactions are less
expressed (higher presence/absence P-value). (4) As different metabolites
have different combinations of production reactions, they cannot be
compared directly within samples. Instead, scores are compared for the
same metabolite between control and treated samples to generate
differential consistency scores using a simple standard score. Once
standardized, metabolites can be compared within drugs to identify regions
where perturbation in production potential has occurred due to gene
expression changes.
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metformin-induced changes supported by previous results
include: (i) a downregulation of folate metabolism consistent
with reported folate deﬁciency in metformin-treated patients30,
(ii) upregulated oxidative stress response consistent with reported
lower reactive oxygen species levels31 and (iii) increased
polyamine synthesis and recycling pathways that may result
from shared use of organic cation transport (OCT) proteins
between metformin32 and polyamines33. Third, treatment with
genistein, an isoﬂavone with hypolipidemic effects34, experimen-
tally showed a preferential reduction of the fraction of mono-
unsaturated fatty acids synthesized from glucose that was
consistent with predictions (Fig. 4c).
Identiﬁcation of in vitro disease-linked metabolic pathways.
Using MetChange scores generated from the CMap data set, we
then identiﬁed the drug-induced metabolic gene expression
changes that are most conserved among drugs with
particular clinically described side effects. We used a machine
learning approach to select discriminating metabolite production
pathway perturbations from the set of MetChange-calculated
pathway changes based upon side effect frequency data
reported in the Side Effect Resource (SIDER) database35
(Figs 1b and 5). A total of 357 side effects across 1,417 gene
expression proﬁles from CMap were analysed, based on the
criterion that at least 30 expression sets per side effect were
available. The cutoff in number of expressions sets was
chosen rationally as a balance between the scale of the study
and the robustness of the side effect signature obtained. Overall,
2,422 disease-linked drug-changed (termed DISLoDGED)
metabolic pathways were identiﬁed with this analysis.
These pathways are MetChange calculated metabolite
production pathways that are over-represented in perturbations
by drugs with particular side effects. DISLoDGED pathways
are potential side effect to pathway relationships, hypothesizing
that drug-induced perturbations away from metabolic
homeostasis are involved in side effect pathogenesis. The
calculated DISLoDGED pathways thus comprise a large set of
omics-driven hypotheses of side effect pathogenic mechanisms
(Supplementary Data 2). These associations were initially
supported by automated co-association searches of PubMed
abstracts to examine disease-linked nutrient deﬁciencies across all
357 side effects (Table 1). Downregulated DISLoDGED pathways
were found to be marginally signiﬁcantly predictive of deﬁciencies
associated with corresponding speciﬁc diseases (permutation
P¼ 0.055), whereas upregulated pathways were not predictive
(permutation P¼ 0.39). We then sought to determine whether
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Figure 3 | Analysis of MetChange analysis of matched transcriptomic/metabolomics data in S. cerevisiae under carbon and nitrogen starvation
conditions using the S. cerevisiae metabolic network reconstruction iMM904. (a) Comparison of the median correlations of computational metabolite
absolute magnitude perturbation predictions with experimental data for several existing methods of integrating gene expression data with a metabolic
reconstruction. (b) The same comparison as in part a, but taking into account the direction of perturbation (the reporter metabolites method is not
directional in its predictions, so both comparisons were made). Error bars are standard deviations. The MetChange algorithm performs favourably on this
data set in both absolute magnitude and directional predictions. (c–e) Principle component analysis of the MetChange scores, gene expression data and
metabolite data for the 60 metabolites that mapped to iMM904. It is seen that the functional association of data is conserved after transformation to
MetChange scores, and the MetChange principle component clustering has topological similarity to both gene expression and metabolite data clustering.
The number of biological replicates in the original study was 1.
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the metabolic expression changes induced by drug treatment were
involved in the pathogenesis underlying drug side effects.
Construction of a database of in vivo links between metabolism
and disease. We assessed the relevance of DISLoDGED metabolic
pathways to side effect pathogenesis through the use of a large
body of clinical, biochemical and genetic literature on
metabolism–disease relationships. We constructed a database of
in vivo links found within the literature between metabolic
function and disease, called the Metabolism Disease Database
(MDDB), that consists of curated primary literature and existing
databases (hosted at sbrg.ucsd.edu/mddb). Data collected through
manual curation of the literature included disease-linked:
(i) metabolic gene variants, (ii) physiological system-speciﬁc
metabolism, (iii) metabolic pathways, (iv) chemical inhibitors of
metabolism and (v) nutrient deﬁciencies and supplements. Data
aggregated from existing databases included metabolic gene var-
iants affecting disease incidences from a large genome-wide asso-
ciation study (GWAS) database36 and drug-metabolic enzyme
target pairs from DrugBank28,29. Studies on disease models were
treated as acceptable sources where clinical data were not available.
The resulting database encompasses 357 side effects, over 280 non-
drug inhibitors, 600 drug molecules, 37 nutrients and over 5,000
investigated metabolic pathway-disease-link associations. The
database includes information related to both drug side effects
and non-drug-induced pathologies, and we examined predictions
in terms of each of these separately.
Comparison of DISLoDGED pathways with side effect
pathogenesis. We ﬁrst examined whether DISLoDGED metabolic
pathways contain genes with variants that alter clinical side effect
susceptibility, according to the data in MDDB (Table 1). Causal
gene variants are typically considered to affect either drug phar-
macokinetics, which involves drug exposure, or drug pharmaco-
dynamics, which involves the interaction of the drug with the
body. The majority of identiﬁed gene variants affecting drug side
effect incidence are involved in drug pharmacokinetics, because
these genes historically have been simpler to identify as drug
metabolism genes are largely known. However, we focused upon
genes affecting pharmacodynamics, as these genes are more
directly indicative of the mechanisms underlying pathogenesis. In
MDDB, we identiﬁed nine side effect susceptibility gene variants
that overlap directly with metabolism but are not involved in
drug pharmacokinetics (Supplementary Note 1). We found that
for each of the nine side effect susceptibility genes, at least one
overlapping DISLoDGED pathway for this side effect had been
identiﬁed through our analysis (Table 2). This overlap between
DISLoDGED pathways and non-pharmacokinetic side effect
susceptibility altering genes was highly signiﬁcant (joint hyper-
geometric tests, P-value 2.2 10 11, see Supplementary Note 2
for calculation).
To support the relevance of this overlap, we assessed the nine
overlapping DISLoDGED pathways in the context of additional
known factors related to side effect pathogenesis (Table 2). We
found that, in each case, the overlapping DISLoDGED pathway
had established ties to the clinical pathogenesis of the side effect
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Figure 4 | Validation in cell culture of drug-speciﬁc metabolic perturbations calculated from drug-induced transcription changes. (a) In the left panel,
gene expression related to vitamin B6 metabolism is downregulated by haloperidol, suggesting decreased utilization of vitamin B6. In the right panel, vitamin
B6 levels were measured by an enzymatic assay in media supernatant and lysates of MCF-7 cells, showing decreased utilization of the essential
nutrient. (b) In the left panel, metformin gene expression perturbations are shown on the left, and resulting MetChange scores for related metabolites are
shown on the right. The right panel shows response of tricarboxylic acid metabolites and acylcarnitines to metformin treatment. Metabolites show a large
perturbation in the opposite direction of the observed transcriptional changes, validating the presence of a perturbation but indicating non-transcriptional
control of metabolite levels in central metabolism as well. (c) In the upper panel, genistein is predicted to preferentially decrease production of
mono-unsaturated fatty acids. The lower panel shows measurement of biosynthesis fraction of different fatty acid groups and precursors from glucose
following genistein treatment measured by NMR spectroscopy, which validate modelling predictions. MUFA: Mono-unsaturated fatty acids. SFA: Saturated
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termination criteria, as obtaining a global optimum was not deemed essential to gain biological insight. (5) The signature yielding the highest prediction
AUC is considered the best predictor set. In the example case, the resultant AUC is 1.0, a perfect predictor for the sample set. (6) To assess over-ﬁtting and
hence the predictive potential of the metabolic signature, tenfold cross-validation is performed by generating ten partitions of 90% of the data to train
signatures and predict the remaining ten partitions of 10% of the data. To ﬁnd signatures that have constant predictive power, the cross-validation
signatures were summed, and high scoring metabolites were considered the conserved metabolic response signature (DISLoDGED pathway) for the side
effect or indication. FPR, false positive rate; TPR, true positive rate; TP, true positive; TN, true negative; FP, false positive; FN, false negative.
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(Table 2, column 5). In the seven cases where the side effect
pathology had been reported independently of the drug,
alterations in the DISLoDGED pathway have been associated
with the disease (Table 2, column 6). Critically, in each of the
nine cases, we found that drugs causing the side effect had been
reported to induce a perturbation in the DISLoDGED pathway
in vivo, demonstrating that the in vitro-derived DISLoDGED
pathways are similarly perturbed in vivo (Table 2, column 7).
Furthermore, in seven of the nine cases, nutrient supplementation
targeted at the DISLoDGED pathways have been shown to be
effective in treating the drug side effect, whereas the remaining
two cases are inconclusive due to reports of both positive and
negative results (Table 2, column 8).
For example, among the 38 drugs within the CMap
database reported in SIDER as causing increased risk of cardiac
arrhythmias, we identiﬁed ﬁve DISLoDGED pathways
(Supplementary Note 1). Three of these DISLoDGED pathways,
which were a downregulation of oxidative pentose phosphate
pathway and two related upregulations in nitrogen metabolism,
overlap with genetic polymorphisms known to cause increased
susceptibility to arrhythmias37–39 (Table 2). These pathways
are known to have physiological ties to the pathogenesis
of arrhythmias40,41 and have been shown to be perturbed
in vivo by drugs causing arrhythmias42,43 (Table 2).
Furthermore, nutrient supplementation targeted at these
pathways has been found therapeutic in drug-induced
arrhythmias44,45 (Table 2). The remaining examples are
presented in Supplementary Note 1.
Comparison of DISLoDGED pathways with general disease
pathways. We further expanded the scope of validation beyond
the nine available cases of non-pharmacokinetic genetic variants
directly affecting side effect incidence. The MDDB database was
used to determine whether the identiﬁed DISLoDGED pathways
Table 1 | Summary of large-scale validation of drug-metabolic perturbation associations predicted by MetChange calculations.
Property Database # Drugs Properties analysed Statistical signiﬁcance
Drug target distance DrugBank 134 536 Target reactions P¼ 1.65 10 10
(Wilcoxon rank sum test)
Drug–protein association PubMed 645 501 Signalling proteins Po0.01 (Permutation test)
Drug–metabolite association PubMed 645 375 Metabolites Po0.001 (Permutation test)
Drug side effect SIDER, PubMed 334 357 Side effects total
299 For co-term analysis
P¼ 5.6 10 2 (Permutation test)
Abbreviation: SIDER, Side Effect Resource.
Table 2 | Existing studies of pharmacodynamic-altering side effect susceptibility genes and overlapping DISLoDGED pathways*.
1
Side effect
2
DISLoDGED Pathway
(# metabolites in
pathway)
3
PD gene
4
Nutrient
overlap
5
Patho-
physiology
6
Metabolic
perturbation
7
In vivo drug
perturbation
8
Supplement
Weight gain Melatonin MC4R MC4R levels
correlated with
melatonin
Melatonin and
MC4R energy
regulators
Decreased melatonin
tied to metabolic
syndrome
Antipsychotics
suppress
melatonin
synthesis
Melatonin
Parkinsonism Poly-unsaturated
fatty acids
ZNF202 ZNF202 lipid
regulator
PUFAs linked to
Lewy bodies
Altered lipid
oxidation
RBC PUFAs altered Essential
fatty acids
Tardive
Dyskinesia
Serotonin 5-HT
receptors
Direct ligand Dopaminergic
neuron
interaction
NA 5-Hydroxy-
indoleacetate
perturbation
Conﬂicting
ﬁndings
Tardive
Dyskinesia
Ascorbate D3 receptors Dopamine
synthesis
cofactor
Dopamine
primary mediator
NA Metabolite levels
perturbed
Vitamin C,
vitamin E
Myotoxicity CoQ10 COQ2 CoQ10
synthesis
Mitochondrial
function
Q10 deﬁciency
associated
w/ myopathy
Decreased under
statin treatment
CoQ10
(conﬂicting)
Cardiac
arrhythmia
Urea cycle NOS1AP Nitrogen
regulation
NO affects
cardiac function
Altered NO linked to
arrhythmia
Various affect NO
production
L-arginine
Cardiac
arrhythmia
Pentose phosphate
pathway
GPD1L, ZFHX3 Oxidative stress
response
Oxidative stress
affects cardiac
function
H2O2 induces
arrhythmia
Clomipramine
induces via
oxidative stress
Various
antioxidants
Hearing loss Ascorbate COMT Dopamine
synthesis
cofactor
Dopamine
innervation in
inner ear
Dopa synth.
inhibition tied to
hearing loss
Cisplatin inhibits
dopamine
Vitamin C,
dopamine
Hearing loss Ascorbate, lipoate Glutathione
S-transferases
Oxidative stress
response
ROS-induced
cochlear cell
death
SOD deﬁciency tied
to hearing loss
Cisplatin induces
via oxidative stress
Vitamin C,
lipoate
Abbreviations: NA, not applicable; PUFA, poly-unsaturated fatty acids; RBC, red blood cell; ROS, reactive oxygen species; SOD, superoxide dismutase; 5-HT, serotonin.
*Existing studies of pharmacodynamic-altering side effect susceptibility genes and overlapping DISLoDGED pathways. The two cases of tardive dyskinesia have ‘NA’ in the ‘Metabolic perturbation in
disease’ row as tardive dyskinesia is not typically described as a disease outside of its occurrence as an adverse drug response, therefore there is no drug-independent case for comparison. See the
Supplementary Note 1 for full discussion and references related to each case.
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are conserved within in vivo data related to non-drug-induced
pathologies as well, where a signiﬁcantly larger body of literature
exists than for side effect pathogenesis. This analysis hypothesizes
that non-drug-induced pathogenesis and corresponding side
effect pathogenesis share a common basis. Using the data col-
lected, we assessed the calculated DISLoDGED pathways in terms
of the ﬁve causal relationships in MDDB. Downregulated and
upregulated DISLoDGED pathways were assessed independently
to examine directional causal relationships. Approximately one-
sixth of calculated DISLoDGED pathways were investigated for
validation, and compared with an equal number of randomized
predictions as a control. The next sections describe each causal
link examined.
Gene variants affecting disease incidence. We ﬁrst sought to
determine whether DISLoDGED pathways contain known
disease-linked gene variants. To do this, we compared the
metabolic subsystems into which disease-linked gene variants and
DISLoDGED pathways occur. We analysed 239 metabolic dis-
ease-linked genes from MDDB and found an enrichment
of disease-linked genetic variants among transporters
(one-tailed hypergeometric P¼ 0.0048) and inositol metabolism
(one-tailed hypergeometric P¼ 0.02), as well as a depletion of
variants in central carbon metabolism (one-tailed hypergeometric
P¼ 0.035). We found that DISLoDGED pathways showed similar
results, including an enrichment of downregulated DISLoDGED
pathways in inositol metabolism (P¼ 0.018) mirroring the
enrichment found in disease-linked genetic variants, as well as
enrichment of DISLoDGED pathways in non-central metabolism
(Supplementary Table 1). These results indicate certain metabolic
pathways may be inherently less robust to pathological
perturbation.
DISLoDGED pathway associations with disease physiology.
Next, we examined whether DISLoDGED pathways are known to
be essential to system physiology in a manner that could result in
disease when perturbed. To compare DISLoDGED pathways to
disease pathophysiology, side effects were grouped based on
affected physiological systems, such as renal diseases or auto-
immune complications. We ﬁrst grouped DISLoDGED pathways
by nearest nutrient for better coverage in the literature (Fig. 6a).
DISLoDGED nutrient pathways preferentially altered by drugs
causing side effects in speciﬁc physiological systems were then
calculated. In 17 of the 18 cases of enrichments of downregulated
DISLoDGED nutrient pathways within particular physiological
systems, the downregulated pathways had directionally consistent
links to the disease pathophysiology (Fig. 6b and Supplementary
Data 2). For example, inositol metabolism downregulation was
enriched among drugs with side effects affecting the kidney,
including kidney failure. Supporting this relationship, the kidney
is a primary site of inositol synthesis46, and inhibition of inositol
transport has been reported to cause renal failure47.
Similarly, pathways that were upregulated by drugs affecting
particular physiological systems also showed directionally
consistent links to pathophysiology. In 9 out of 17 DISLoDGED
nutrient pathways that were upregulated in particular
physiological systems, inhibitors targeted at the upregulated
pathway were established therapeutics within the disease class
(Fig. 6c). For example, drugs causing cancer- or autoimmune-
related side effects were enriched in upregulation of folate
metabolism, and anti-folates are commonly used in treatment of
diseases in both classes. Supporting the implications of this
upregulation in side effect pathogenesis, studies have shown that
folate supplementation is tied to increased incidence of both
cancer48 and childhood asthma49.
Altered activity of DISLoDGED pathways in disease. We
then sought to determine whether DISLoDGED pathways are
signiﬁcantly over- or under-active in corresponding clinical
disease and disease models, based on several metrics in the
MDDB. To perform this analysis, DISLoDGED metabolic
pathways were associated with dietary nutrients nearest in the
metabolic network. In an initial analysis of 323 DISLoDGED
nutrient pathways, downregulated DISLoDGED pathways
were found to be signiﬁcantly enriched in disease-associated
nutrient deﬁciencies (59% enrichment, binomial P-value 0.0017),
whereas upregulated DISLoDGED pathways were depleted in
disease-associated nutrient deﬁciencies (47% depletion, binomial
P-value 0.036; Fig. 7a).
These results were conﬁrmed in an independent set of 453
investigated DISLoDGED pathways added to MDDB.
Downregulated DISLoDGED pathways were more likely to have
a causal downregulation associated with the corresponding
pathology (17% enrichment of downregulation, binomial
one-tailed P¼ 0.045; Fig. 7b), whereas upregulated DISLoDGED
pathways were signiﬁcantly predictive of consistently over-active
pathways tied to corresponding pathologies (67% enrichment of
over-activity, binomial one-tailed P¼ 0.003; Fig. 7c).
Effect of targeted inhibition of DISLoDGEDmetabolic pathways.
Next, we analysed in vivo data on the effect of non-drug chemical
inhibitors targeted at calculated DISLoDGED pathways. A causal
relationship would be indicated by (i) inhibitors targeted at
downregulated DISLoDGED pathways reproducing the clinical side
effect and (ii) inhibitors targeted at upregulated DISLoDGED
pathways treating the clinical disease. We found that metabolic
inhibitors targeting downregulated DISLoDGED pathways speciﬁ-
cally were signiﬁcantly more likely to cause corresponding side
effects (28% enrichment, binomial one-tailed P¼ 0.04; Fig. 7d).
Also, we found that both downregulated and upregulated DIS-
LoDGED pathways were more likely to be known targets for
effective metabolic inhibition to treat corresponding diseases,
indicative of imperfect directionality of predictions (64% enrich-
ment, binomial one-tailed P¼ 0.0015 and 29% enrichment, bino-
mial one-tailed¼ 0.09, respectively; Fig. 7e).
Effect of supplementation targeted at DISLoDGED pathways.
Finally, we compared calculated DISLoDGED pathways grouped
by nearest nutrient with clinical therapeutic nutrient
supplementation data (Fig. 6a). We sought to determine whether
downregulated DISLoDGED pathways might be targets for
nutrient supplementation as a disease therapy. We observed
that predicted downregulated DISLoDGED pathways were
preferentially targets of nutrient supplementation to alleviate
corresponding pathologies (24% enrichment, binomial one-tailed
P¼ 0.065; Fig. 7e), whereas overexpressed pathways were
preferentially depleted as effective nutrient supplements
(19% depletion, binomial P¼ 0.14), although the relationships
did not reach statistical signiﬁcance for given sample sizes
available.
Discussion
The systems biology-based workﬂow developed in this study
predicts side effect-linked dysregulated metabolic pathways
(termed DISLoDGED pathways) from drug treatment of human
cells in culture. We contextualize numerous independent data
types that together support a key role of drug-induced non-
pharmacokinetic metabolic dysregulation in side effect pathogen-
esis. Through the construction of a comprehensive resource on
metabolic involvement in disease, we corroborate the predictions
made using ﬁve independent clinical, genetic and biochemical
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bodies of the literature. These results provide understanding of
the mechanisms underlying side effect pathogenesis, which have
remained largely opaque despite recent progress identifying
causal protein-binding events and genetic susceptibility factors.
The work presented relied upon the development of a systems
biology workﬂow to identify side effect-linked features and
validate the relevance of these features using historical in vivo
data. The use of systems biology approaches to study drug side
effects has become an active ﬁeld in recent years. Previous studies
have predicted drug–protein-binding events responsible for side
effects9,50, effective combinations of drugs to minimize side
effects51, and drug mechanisms of action underlying side effect
pathogenesis12,52. Still, uncovering how causal binding events
result in disease is an essential and largely unanswered question,
as identiﬁed pathogenic mechanisms can potentially be used to
design therapies to circumvent drug side effects. The present
work we believe is the ﬁrst to validate omics-driven predictions of
post-binding mechanisms underlying side pathogenesis using
clinical data at a large scale, which was empowered by the
generation of a new database through manual curation of the
literature.
The workﬂow presented is highly dependent upon large
amounts of gene expression data obtained under treatment by
diverse drugs to ﬁlter out perturbations due to factors other than
common side effects. Normalization of data across multiple
studies and platforms is a substantial issue. Thus, data generated
within a single study is ideal, but such large studies are rare. For
this reason, the potential to extend the workﬂow to new data
types, for example, in vivo gene expression data, may be limited.
Owing to the use of in vitro data, corroboration against in vivo
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Figure 6 | Maps of interactions between DISLoDGED pathways grouped by nutrient domain and corresponding side effects grouped by disease class.
Only nutrients and disease classes with at least one marginally enriched nutrient-class interaction (hypergeometric Po0.1) are shown. (a) Using the
metabolic network reconstruction Recon 1, side effect-speciﬁc metabolic perturbations (DISLoDGED pathways) are grouped into nutrient domains to
enable comparison with existing disease-related genetic, clinical and pre-clinical data to assess the potential causality of observed perturbations. In this
ﬁgure, the number of side effects with an upregulation in the production pathway for a metabolite is shown in yellow boxes, whereas blue boxes show
the number of side effects with a downregulation in the production pathway for a metabolite. (b) Downregulated DISLoDGED pathways. Nutrient-disease
class interactions indicating an enrichment of downregulations in drugs causing side effects within the class are coloured according to the legend.
(c) Upregulated DISLoDGED pathways. Nutrient–disease class interactions indicating an enrichment of upregulations in drugs causing side effects within
the class are coloured according to the legend. Many of the enriched interactions are consistent with known effects of nutrient/pathway perturbation on
the corresponding disease classes and physiological systems.
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data appears critical. Further deployment of the presented
workﬂow may hinge upon expansion of curated disease data
necessary to corroborate the clinical relevance of in vitro drug
treatment features. Furthermore, the deﬁnition of pathways used
to integrate disparate data types has yet to be concretely
established and may be an area for further workﬂow
optimization.
Owing to the ubiquity of gene set enrichment analysis
(GSEA)53 in pathway-based analysis of gene expression, a
discussion on the differences between the MetChange algorithm
and GSEA is warranted. Both methods attempt to aggregate
‘signal’ in gene expression data along pathway deﬁnitions to
increase the interpretability of the data and decrease the effect of
noise. GSEA uses a variety of pathways, including manually
curated metabolic pathways, and results are typically P-values of a
Kolmogorov–Smirnov test for the likelihood that the cumulative
distribution of expressions of genes in each pathway have not
changed between conditions. MetChange deﬁnes a different
production pathway for each metabolite in the network, based on
calculation of functional states of the metabolic network, and
scores for each metabolite how gene expression along this
production pathway has changed between conditions. As a result,
MetChange has the potential to give ﬁner resolution results, as its
results are deﬁned at the level of individual metabolite scores
rather than pathway scores. However, the overall performance of
the methods are difﬁcult compared due to the fundamental
difference in resolution of outputs.
In the comparison between MetChange and comparable
methods (Fig. 3), it is apparent that, on the data set used, output
correlations of none of the methods with measured metabolite
perturbations in yeast were particularly high. However, given
that this analysis is possibly using these methods out of their
intended use cases, no presumptions should be made regarding
the general usefulness of any of these methods. Rather, this may
highlight the difﬁculty in establishing standards by which to
compare pathway analysis algorithms with statistical rigor. In this
study, we performed the analysis primarily to provide some
context for the relative performance of the MetChange algorithm
at one speciﬁc task relevant to predicting metabolic changes
occurring within the cell. We note that a recent method to predict
metabolomics changes from gene expression has reported
statistically signiﬁcant correlations on three other yeast data
sets54, including values that exceed those reported in Fig. 3.
There are at least two obvious potential improvements that
could be made to the workﬂow used in this work. First, as the cell
lines within the CMap are within the NCI60 cell line panel, and
expression, growth and most recently exometabolomic12 data
have been measured for these lines, cell-speciﬁc metabolic models
could be used in place of a global model. Second, the human
metabolic network reconstruction has been updated with the
publication of Recon 2 (ref. 55), and thus improvements might be
made from the increased scope of the model. We evaluated the
potential for improvements using these changes by constructing
cell-speciﬁc models for the MCF-7, HL-60 and PC-3 cell lines
based on Recon 2 and running the MetChange algorithm on
randomized simulated expression data drawn from an empirical
distribution of MAS5.0 normalized P-values from the CMap data
used in this study. Brieﬂy, between cell-speciﬁc Recon 2 models,
error was between 10 and 25% across replicates when given the
same metabolite uptake constraints. The largest difference
observed was by enforcing measured metabolite uptake
constraints. Differences in MetChange scores between models
constrained and unconstrained by metabolite uptakes were
around 70%, indicating that signiﬁcantly constraining the ﬂux
state of the model alters MetChange scores more so than
topological differences. Thus, further improvements in prediction
accuracy might be seen by accounting for the baseline metabolic
differences between cell lines.
One interesting outcome of the work was that, although
previously identiﬁed genetic susceptibility factors in the literature
are dominated by genes involved in pharmacokinetics, we observe
overlap of drug-induced metabolic changes with nine genes that
affect pharmacodynamics. This may suggest that such non-
pharmacokinetic genes may play a larger role in side effect
pathogenesis than currently appreciated. We did, however, see
some alteration of pharmacokinetic genes in a few cases as well
(Supplementary Note 3). In addition, DISLoDGED pathways
overlapped with clinical disease-linked pathways for both drug-
treated and drug-independent studies, suggesting a common basis
in pathogenesis. Furthermore, our results suggest that targeted
nutrient supplementation may be a relatively simple and
inexpensive path to broadly reduce side effect incidence. The
impact of drugs on patient metabolic status is thought to be an
underappreciated but important aspect of drug response56, and
this work further suggests this interaction is worthy of signiﬁcant
investigation. Patient attrition may be reduced through effective
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nutrient supplement to drug pairing during the development
process.
A natural question that may arise is whether certain pathways
or side effect disease classes are more successfully predicted by the
method used in this work than others. A sensitivity analysis
shows that the method appears to be fairly robust in being able to
predict DISLoDGED pathways in various areas of the metabolic
network and across disease classes. Restricting to at least ﬁve pairs
investigated for both the down-regulated DISLoDGED pathways
and random pairs, deﬁciencies of nine nutrients (polyunsaturated
fatty acids, coenzyme Q10, melatonin, niacin, riboﬂavin, steroids,
thiamine, vitamin A and vitamin D) had disease associations
better predicted by down-regulated DISLoDGED pathways
compared with random, whereas one (choline) did not. Similarly,
in side effects with at least two pairs investigated in both random
and real, seven side effect/nutrient deﬁciency relationships were
better predicted by down-regulated DISLoDGED pathways
(dyspepsia, epilepsy, hyperlipidemia, interstitial nephritis, tardive
dyskinesia, testicular atrophy, and thrombocytopenia), whereas
only two were better predicted by random nutrients (ecchymosis
and tendonitis). These types of sensitivity analyses on predictive
capability for particular nutrients and side effects are vulnerable
to error because of small sample size but corroborate overall
results that dysregulated DISLoDGED pathways are predictive of
metabolic pathways associated with corresponding pathologies.
Although challenges remain, the ability to observe perturba-
tions important to in vivo side effect susceptibility within in vitro
data suggests that early-stage drug screening to identify and
manage side effect risk may become possible, analogous to other
‘disease in a dish’ efforts57. Notably, high use drugs such as statins
and antipsychotics, where patient populations are large enough
for statistical analysis of rare side effect events, dominate cases of
side effects where genetic components have been identiﬁed.
However, if vulnerable pathways can be identiﬁed through
analysis of in vitro data, it may become easier to identify
susceptibility factors for more rare disease classes as well. This
workﬂow is currently limited to cases in which gene expression
alteration underlies side effect pathogenesis, which is an
undeﬁned subset of all side effects. The results presented show
the utility of integrating large, standardized data sets, such as the
CMap, with clinical data types such as side effect incidence,
genetic studies and disease–nutrient associations, in the context
of a highly annotated network with clear functional connections.
Such integration of disparate data sources is a key challenge in
many areas of the life sciences today.
Methods
Overview of computational approach. As described schematically in Fig. 1, with
more detailed methods diagrams in Figs 2 and 5, we employed a combination of
constraint-based modelling and machine learning to look for metabolic gene
expression perturbations that are conserved in adverse drug reactions. The ﬁrst
step is the analysis of drug-speciﬁc metabolic perturbations using the constraint-
based MetChange algorithm described below and comparison of these perturba-
tions to drug-speciﬁc response properties. We then combined MetChange scores
based on side effects and used an area under the Receiver Operating Characteristic
curve (AUC)-maximizing classiﬁcation genetic algorithm described below to
determine small subsets of metabolic changes highly conserved in certain side
effects. We note in general that the ﬁelds of constraint-based modelling and
machine learning have developed a wide variety of methods that perform similar
tasks. We compare our method with several other constraint-based methods and
with gene expression data alone, as described in the Results. We also qualitatively
contrast our method with GSEA53 in the Discussion. In general, performance of
machine learning methods largely depends on the particular problem. We note that
in cases of rare events, such that only a small fraction of samples have a property,
AUC (or rank) maximizing algorithms have been shown to perform particularly
well. In addition, we choose to place a hard constraint on the number of variables
rather than using a traditional SVM with an L2-norm approach, for example. This
was done to maximize interpretability of the resulting signatures, which was critical
for later comparison of DISLoDGED pathways with pathology deﬁciency
relationships and disease-linked and side effect-linked genetic susceptibilities.
Thus, although we do not discount that other methods may exhibit better
performance by certain standards, we chose our approach to meet the speciﬁc
requirements of our problem, as is typical in the ﬁeld. Full description of methods
is below and a MATLAB implementation is provided (see Supplementary
Software).
CMap data processing and integration. Gene expression data for the AffyMetrix
HT Human Genome U133A platform were obtained from the CMap database22 for
MCF-7, PC-3 and HL-60 cell lines. Data were MAS5.0-normalized with the
BioConductor package58. Human Entrez Gene identiﬁers associated with probes
were used to map detection P-values to their corresponding reactions based on the
Boolean gene–protein–reaction associations as was previously described59.
Reactions that were not associated with a gene were assigned a P-value of 0.
Metabolic exchange was set to an exchange value of  1 for DMEM (MCF-7)
or RPMI (PC-3 and HL-60) media metabolites. In cases where no metabolite
production was possible with open constraints, the metabolite was removed from
further analysis. For the cases of in vitro experimental validation under genistein
treatment, for which data was generated for the fraction of metabolites generated
from glucose, the MetChange algorithm was run using glucose as the sole carbon
source to enable direct comparison with the data.
The MetChange algorithm. The Metabolite-Centered Hotspots of Altered Net-
work Gene Expression (MetChange) algorithm was used to analyse differential
quantitative gene expression proﬁles in the context of a genome-scale metabolic
network19. This algorithm is built upon the Gene Inactivity Moderated by
Metabolism and Expression (GIMME) algorithm previously developed to build
context-speciﬁc metabolic networks based on gene expression data59,60.
The MetChange algorithm deﬁnes a consistency metric of an expression proﬁle
with optimally producing each metabolite in the metabolic network. For each
metabolite, a sink reaction is created and ﬂux through the sink reaction is
maximized using ﬂux balance analysis:
vmax;i ¼ max½cv;i  v  S  v ¼ 0; a  v  b ð1Þ
where S is the stoichiometric matrix, v is the reaction ﬂux vector, a and b are
vectors for the lower and upper bounds of the reactions and cv,i corresponds to the
imposed reaction objective for each ith sink reaction. This results in a set of optimal
production ﬂuxes for each network metabolite.
Each reaction is then weighted by a detection P-value from mapped expression
data to solve a second optimization problem. To obtain metabolite production
‘consistency’ scores, xi, for each ith metabolite, scores were generated by setting the
lower bound of the metabolite sink reaction to its maximal production ﬂux, vmax,i,
and minimizing the inner product of the reaction detection P-values:
xi ¼ min½cp  v  S  v ¼ 0; a  v  b; ai ¼ vmax;i; ð2Þ
where mapped detection P-values p were stored in a weighting vector cp, and each
vector component cp,i¼ pi mapped to each ith reaction. This optimization is the
GIMME algorithm-like step of the MetChange algorithm. Each ith component in
cp serve as a cue for whether a reaction is detected or absent (that is, a lower P-
value indicates a reaction is more likely to be present). Hence, this second
optimization determines: (i) a ﬂux distribution which maximizes the production of
a metabolite and (ii) generates a weighted ﬂux distribution score deﬁning
consistency of the production of that metabolite with expression data. These scores
cannot be directly compared across metabolites because of the fact that each
metabolite has a different network ﬂux state at maximal production. Thus, we
compared metabolite production consistency scores between treated and control
samples with a standardized score:
Zmet;j ¼
xtreated;j  mcontrol;Nj
scontrol;Nj
; ð3Þ
A MATLAB implementation of the MetChange algorithm is provided in the
Supplementary Software File.
Analysis of expression data for yeast under carbon and nitrogen starvation.
Metabolite concentration25 and gene expression26 data for S. cerevisiae were
mapped to a genome-scale yeast metabolic reconstruction, iMM904 (ref. 26). For
all methods, scores were compared to log-2 metabolite concentration changes
relative to the initial time point for carbon or nitrogen data. Spearman correlations
were calculated to avoid biases due to variable score distributions among the
different methods. K-means clustering analysis was performed using 100 replicates.
In all cases, the same clusters were obtained in repeated runs.
For the MetChange algorithm, reported expression values were used to generate
reaction presence/absence P-values. Expression values were ranked, and based
upon the apparent distribution, a value corresponding to the bottom second
percentile of expression was used to deﬁne the noise level. Expression values below
this threshold were assigned a P-value of 1 as ‘not present.’ The P-values below the
threshold were then inverted across the threshold to generate a symmetric
distribution. The mean and standard deviation of this approximated noise
distribution were used to generate signiﬁcance scores for the remaining expression
values using a Z-test. These P-values were then mapped to reactions based on
model-deﬁned gene–reaction relationships. When multiple probes were assigned
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the same reaction, the minimum value was used. The MetChange algorithm was
then applied using these mapped reaction presence/absence P-values. As the data
were longitudinal in time and multiple controls were not available, log-2 scores
were calculated with respect to the initial time point, rather than taking standard
scores.
Reporter metabolite analysis was then implemented. P-values for the
signiﬁcance in expression change were used as inputs to the reporter metabolite
analysis. Each expression value was ﬁrst standardized across conditions and then
P-values were calculated using a standard Z-test for each gene across condition.
10,000 permutations of the data were used to generate the background levels of
perturbation.
In addition, the E-Flux method was implemented18, with metabolite sinks set as
separate objective reactions similar to the MetChange algorithm for comparison.
Optimal ﬂux through each metabolite sink reaction was then calculated using ﬂux
balance analysis for each gene expression data set, and log-2 scores compared with
the initial time point for each carbon and nitrogen data set were calculated.
For a direct comparison with gene expression level cues, we implemented the
following approach. First, standardized scores of expression level changes were
calculated with respect to all gene expression data sets for the particular
perturbation (carbon or nitrogen starvation). The scores were mapped to their
respective reactions according to the gene–reaction association in the metabolic
network. We then assessed whether absolute changes in expression levels are
predictive of the magnitude of metabolite change by adding the standardized
reaction scores, weighted by the absolute stoichiometric coefﬁcients. We then
assessed whether higher gene expression for a reaction was indicative of a higher
product concentration and lower reactant concentration. The mapped reaction
score was added to the score for all metabolites in the reaction, multiplied by the
signed stoichiometric coefﬁcient for each metabolite.
Analysis of metabolic response phenotypes across drugs. The Recon 1
metabolic network19 was ﬁrst converted into an irreversible network, such that each
reaction proceeds only forward, and reactions that can proceed in multiple directions
are split into two forward-proceeding reactions. The MetChange algorithm was run
using gene expression presence/absence MAS5.0 P-values from the CMap database
build 02 (ref. 22). When multiple controls were present, a standard score was
generated. When a treated sample was from a batch with a single control, the mean
and standard deviation of all control samples was used instead.
Cell line standard scores were then generated in the following manner. First, for
each cell line, the median scores of all samples for each drug were found and used as
the cell line-speciﬁc response. Then, to simplify compartment-speciﬁc scores to a
general metabolite response, cytosolic metabolite scores were taken when available. If
no cytosolic metabolite existed, the median of scores across all compartments was
taken as the metabolite score. Finally, a standard score across all drugs was calculated
for each cell line. Consensus drug perturbations across cell lines were calculated by
averaging cell-speciﬁc MetChange scores and standardizing across all drugs.
PubMed querying of drug associations. To identify drug-metabolite associations
in the literature in an automated manner, PubMed/MEDLINE records were
downloaded from the National Library of Medicine and abstracts were parsed to raw
text. Chemical entities were tagged using Reﬂect61. A training set of 44 abstracts
describing true drug-metabolite correlations (positive set) and 150 abstracts with
other chemical entities (negative set) were used to train a Bayesian network to
recognize abstracts that mention the causative relationship between an administrated
drug and the presence of a certain metabolite. A second Bayesian network was
trained to recognize sentences within the abstracts that refer to metabolites from
those that refer to other chemical entities. For each drug-metabolite co-occurrence
the two Bayesian networks were used to assign a posterior for abstract occurrence
and a posterior for sentence occurrence and the joint probability of the two
posteriors was used as the drug–metabolite score. The evaluation of the output is
provided in Supplementary Data 1. The text-mining output was evaluated using a
random sample of 100 pairs. The abstracts that describe each sampled pair were
manually checked and identiﬁed as true or false positives. The score cutoff was set to
0.33, which provides an 82% true positive rate and 70% accuracy.
Text querying on side effect–metabolite, protein–metabolite and drug–protein
co-occurrences were performed using the Entrez Programming Utilities (NCBI)
using a simple ‘AND’ speciﬁcation. Side effects were obtained from the SIDER
database35. Signalling protein lists were obtained from various publically hosted
resources including the International Union of Basic and Clinical Pharmacology
database (http://www.iuphar.org/). Metabolite common names were obtained from
the Recon 1 network reconstruction19. All associations are included in
Supplementary Data 1.
Determining metabolite network distance from drug perturbation. To calcu-
late network distance from metabolites, the DrugBank database28,29 was
downloaded and cross referenced with drugs from CMap. A total of 134 drugs
present in CMap have targets in Recon 1 reported in DrugBank. Across the three
cell lines (HL60, MCF7, PC3) and multiple drug concentration ranges, there were a
total of 611 expression proﬁles of drug-perturbed states. The median metabolite
network distance of each metabolite was calculated for each of the 134 drugs,
ignoring metabolites with reaction connectivities greater than 30, such as cofactors,
protons and water.
MetChange scores were compared against expression data, randomized data
and reporter metabolite analysis results. Data and scores were pooled into bins
based on their standard scores. For each bin, the average of the median network
distance of metabolites to metabolites of known drug-targeted enzymes was
calculated for comparison. Metabolites predicted from the expression data set were
determined by taking the highest expression change among reactions involving the
metabolite and binning accordingly. The random data set was generated by
permuting the expression data set 1,000 times and calculating the average bin value
across all 1,000 sets. The reporter metabolite data set was generated as described in
the original publication24 using 10,000 permutations to generate background
perturbation levels.
Analysis of drug-signal protein signatures. Drug–protein and protein–
metabolite literature co-associations were found as described. Associations were
binary based on the presence or absence of known literature association. A receiver
operating characteristic (ROC) curve was generated for the ability of MetChange
scores to indirectly predict drug–protein association. MetChange scores for all
three cell lines (not averaged) were used together. At increasing thresholds from 0
to effectively inﬁnity, metabolites with absolute MetChange scores greater than the
threshold were scored as signiﬁcantly changed for each drug. Proteins associated
with perturbed metabolites were then determined using the protein–metabolite
literature co-associations. These proteins were used as guesses for true drug–
protein literature associations for the drug corresponding to the sample, and the
true positive rate and false positive rate were calculated. Varying the threshold from
0 to effectively inﬁnity then generates the ROC curve. To assess statistical sig-
niﬁcance of the resulting AUC, 1,000 permutations of MetChange scores were
analysed in the same way and a non-parametric rank test was conducted on the
resulting AUCs.
Determination and analysis of drug side effect signatures. Drug side effects
were taken from SIDER database33 for available drugs overlapping with the CMap
database. The SIDER database contains minimum and maximum occurrence
frequencies for a number of both treated and control studies for each drug–side
effect pair. Side effect frequencies were processed in the following manner. The
mean of the minimum and maximum frequency was calculated for each study, and
then the median of frequencies from all studies was found for both treated and
placebo studies. The difference between treated and placebo occurrence frequency
was then calculated. If placebos were not available, the treated frequency was used.
These frequencies were then mapped to all expression samples from CMap
corresponding to the appropriate drugs. A minimum of 30 expression sets for a
side effect were required for inclusion in the analysis. A total of 357 side effects
were analysed for 850 expression sets corresponding to 334 drugs.
A genetic algorithm was then implemented, termed SiderFinder (Fig. 5). The
matrix of MetChange scores for the 850 expression sets was input as well as the
corresponding side effect frequencies for a particular side effect. A maximum
number of predictor metabolites was set to 20 metabolites. A set of 125 candidate
solutions were generated, assigning values of  1, 0 or 1 to each metabolite to
indicate negative, no or positive prediction of a high MetChange metabolite score
on occurrence of side effect. Each expression set was then scored for the side effect
for each individual by multiplying the predictor set for the individual by the
MetChange scores for the expression set. These side effect scores were ranked and a
pseudo-ROC curve was generated by comparison of scores with the side effect
frequencies for the current side effect. At each threshold, expression sets with a side
effect score greater than the threshold were called as having the side effect. To
weigh more heavily affecting samples with higher side effect frequency, the base 10
logarithm of each side effect frequency was taken and adjusted such that the lowest
non-zero frequency had a value of 1, each order of magnitude greater in frequency
is a unit greater, and all zero frequency side effects remain zero. An ROC curve was
then calculated with true positive hits being assigned the value of the adjusted side
effect frequency, with no effect to false positive, true negative and false negative
values. The number of true values was taken to be the sum of the adjusted
frequency vector so the AUC of the pseudo-ROC still spans 0 to 1. The AUC of this
curve was then used as the objective function to maximize in the genetic algorithm.
Tenfold cross-validation was performed, and perturbations that appeared
cumulatively in at least four of the ten sets we selected. Using the genetic algorithm
directly on gene expression data achieved similar classiﬁcation performance
(results not shown), but metabolite scores were chosen as the variables due to their
previously established performance in predicting drug-speciﬁc metabolic
perturbations.
Genetic algorithm creation, mutation and crossover parameters were used as
implemented in the OptGene function of the COBRA Toolbox 2.0 (ref. 62). The
genetic algorithm was solved using the Global Optimization Toolbox in MATLAB
(MathWorks). A MATLAB implementation is provided.
Co-association analysis of drug side effect signatures. Statistical analysis of
literature co-associations of side effects with side effect metabolite signatures was
performed with (i) a non-parametric permutation test on the drug side effect
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metabolite signatures against 1,000 permutations of the signatures for the AUC of
predicting presence/absence of literature side effect/metabolite co-association in
PubMed abstracts and (ii) a hypergeometric test for the enrichment of literature
association among side effect/metabolite pairs in predicted signatures.
Construction of MDDB. To enable statistical analysis of predicted DISLoDGED
pathways, disease–nutrient pairs were randomly selected from observed down-
regulations, observed upregulations and random associations chosen by resampling
the former two lists through bootstrapping. These disease–nutrient pairs were then
evaluated for existence of established relationships using manual literature searches
while blind to the origin of the pair to prevent investigator bias. The list of collected
metabolism–disease relationships is not yet comprehensive because of the scope of
the effort, but instead relationships were investigated in a targeted manner.
Data collection for the database covered literature up to and including
May 2013.
Pathway analysis. We curated a database of 1,394 distinct GWAS publications34
and extracted 239 distinct disease-associated metabolic genes that overlapped with
the 1,496 genes in Recon 1. We then assigned pathways to each disease-associated
metabolic gene as well as to each DISLoDGED pathway calculated in our analysis
(Supplementary Data 1). Disease-associated genes were assigned pathways based
on the previously assigned pathway of corresponding reaction assigned in Recon 1.
DISLoDGED pathways (which are metabolite centred) were associated with
disease-linked pathways by determining the most frequent pathway among all
reactions in which a metabolite takes part. To assess enrichment, hypergeometric
tests were performed to determine whether the observed coverage of metabolites or
genes was enriched or depleted in particular pathways, controlling for multiple
hypothesis testing.
Side effect pathophysiology classiﬁcations. To assess whether common meta-
bolic perturbations were observed among related diseases, we manually grouped
side effects by pathophysiological disease class. Enrichment was assessed with the
hypergeometric test, at a signiﬁcance level of a¼ 0.1. Enrichment where there was
only a single disease within the class was discarded, as were in conﬂicting cases (in
which a nutrient was downregulated in certain diseases in the class and upregulated
in others).
Side effect-linked gene polymorphism search. We attempted to identify all cases
of genetic basis for side effect incidence reported in the literature, including GWAS
and targeted genetic studies. To be eligible for comparison, we required that the side
effect be a near or exact match and the metabolic pathway of the susceptibility gene
be within the scope of our model. For example, immune-related genes were excluded
due to nonspeciﬁc metabolic association, whereas G protein–coupled receptors
known be regulated by particular metabolic pathways were included. We generally
excluded genes related to drug pharmacokinetics, including drug metabolism and
transport, as the effects of polymorphisms on susceptibility are generally nonspeciﬁc
to the pathology. We also required that the pathology be manifested in nucleated
cells (that is, excluding red blood cell pathologies), as gene expression changes are
assumed to be irrelevant to pathologies of enucleated cells. Based on these criteria,
well over 20 studies were excluded, whereas 9 genetic susceptibilities spanning 6 side
effects were valid for comparison with predictions. We also mention two cases in
which pharmacokinetic genes do overlap with conserved side effect-linked gene
perturbations, suggesting possible interactions between pharmacokinetic and gene
expression effects of drug perturbation. Lists of included and excluded studies are
found in Supplementary Notes 3 and 4, respectively.
Nutrient deﬁciency literature search. To populate MDDB, we searched the
literature for associations between the pathology of the side effect and deﬁciency
relationships between the closest nutrient to the metabolic perturbation and the
occurrence of the pathology of the side effect. In an automated search, PubMed
abstracts were searched for a number of side effect and nutrient synonyms along
with a list of deﬁciency synonyms (Supplementary Data 2). Statistical signiﬁcance
of enrichment of co-association PubMed abstract hits (presence/absence) among
downregulated and upregulated nutrient pathways was assessed through a dual
permutation analysis. For each perturbed side effect–nutrient pair, 1,000 permuted
pairs were generated by ﬁrst randomly selecting the presence/absence result for a
random nutrient with the same side effect, and then randomly selecting the pre-
sence/absence result for a random side effect with the same nutrient, then aver-
aging the result. Then, the number of permutations with total presence calls greater
than the true observation was counted and divided by the total permutations, as is
typical in permutation tests.
In the manual alteration search, a number of possible nutrient–disease
relationships were identiﬁed, such as an inhibitor of the metabolic pathway causing
the side effect, an inhibitor of the metabolic pathway curing the side effect and so
on (Supplementary Data 2). Then, search terms were generated using synonyms,
and PubMed was searched. ‘Results were then ﬁltered such that each nutrient–side
effect pair was assigned as ‘upregulated activity associated with the disease’,
‘downregulated activity associated with the disease’, ‘no associated with the disease’
or ‘conﬂicting associated with the disease’. Inconsistent results were assigned as
conﬂicting and were excluded from further analysis.’ Signiﬁcance of enrichments of
particular relationships among upregulated and downregulated pathways were then
evaluated with the hypergeometric test.
In the manual deﬁciency search, deﬁciency relationships were deﬁned such that
the DISLoDGED nutrient pathway could meet any of three possible criteria to be
considered a ‘hit.’ First, the deﬁciency of the nutrient could be known to be
associated with the occurrence of the side effect pathology. Second,
supplementation with the nutrient is known to alleviate the side effect pathology.
Third, a physiological dysregulation of the pathway is known to be associated with
the side effect pathology. PubMed and Google Scholar were both used for this
study. Patents were not accepted as valid references, unless associated with a
peer-reviewed publication.
To determine whether DISLoDGED pathways are signiﬁcantly predictive of
side effect/nutrient deﬁciency relationships, we generated a list of ‘random’ side
effect/nutrient pairs for comparison with DISLoDGED pathway–disease pairs
through resampling of the pairs. Kolmogorov–Smirnov tests were used to ensure
the distributions were not signiﬁcantly different between DISLoDGED pathways
and random side effect–nutrient pairs in terms of the frequency of occurrence of
nutrients, as resampling should guarantee.
We then performed the nutrient deﬁciency literature search in two phases. The
ﬁrst was blinded and the second was an expansion and additional curation of the
blinded study. The initial study was blinded to ensure that there was no selection
bias in the search process. Random pairs were mixed with DISLoDGED pathways,
both upregulations and downregulations, and information on their origin was
removed. The literature searches for deﬁciency relationships were then conducted
by investigators not involved in the generation of the distribution and thus were
unaware of the treatments or treatment distributions. Statistical tests were only
performed on the blinded literature results. The initial blinded list was then
expanded to examine additional DISLoDGED pathways and curated to ensure
consistent criteria between investigators. Although the curated list is unblinded, we
have a greater conﬁdence in this list for research purposes due to the consistent
criteria and expanded list of investigated relationships.
Overview of experimental validation of MetChange results. Drug-induced
metabolic perturbations calculated using the MetChange algorithm were validated
using in vitro experiments in the MCF-7 cell line for three drugs: metformin,
genistein and haloperidol.
Sample preparation. Human MCF-7 breast carcinoma cells (American Type
Culture Collection, HTB-22) were maintained in supplemented DMEM media
(CellGro Mediatech, 10013CV) with 10% (v/v) fetal bovine serum (Hyclone,
SH3039603), 1% (v/v) antibiotic/antimycotic solution (Omega Scientiﬁc, PS-20),
1% (v/v) non-essential amino acids (Hyclone, SH3023801), 1% (v/v) MEM vita-
mins (CellGro Mediatech, 25020CI), 1mM L-glutamine (CellGro Mediatech,
25005CI). 4 106 cells were seeded in supplemented MEM medium (CellGro
Mediatech, 15010CV) into 150mm dishes. For labelling with [U-13C] glucose
(Sigma-Aldrich, 389374), the medium was replaced with supplemented MEM with
2 g l 1 glucose total of which 50% was [U-13C] glucose. Approximately 2.0 109
cells were harvested by incubation with trypsin for 5min at 37 C (Gibco, 25200-
056) and adjusted for total protein amount (Thermo Scientiﬁc Pierce, 23227).
Intracellular polar metabolites were extracted by rapid quenching with 50%
methanol at  40 C; total lipids were extracted using chloroform (Sigma-Aldrich,
366919). The cell extracts were dried by vacuum evaporation. Organic acids were
derivatized to form the corresponding oximes and trimethylsilyl derivatives. Acyl-
carnitines were derivatized to their corresponding methyl esters. Polar metabolites
were dissolved in 99.9% 2H2O with 0.75% 3-(trimethylsilyl)propionic-2,2,3,3-d4
acid (Sigma-Aldrich, 293040). Lipophilic metabolites were dissolved in
2H-chloroform with 1% tetramethylsilane (Sigma-Aldrich, 151831).
Drug treatment. Cells were exposed for a 24 h period to varying drug con-
centrations (as indicated in their respective citations below) while control cells were
exposed to the corresponding DMSO (CAS 67-68-5, Sigma-Aldrich, D8418)
dilution: metformin (glucophage; CAS 1115-70-4, 15169101, MP Biomedicals,
stock 3M in PBS), genistein (CAS 446-72-0, 10005167100 Cayman Chemicals,
stock 100mM in DMSO), haloperidol (haldol; CAS 52-86-8, 15369690 MP Bio-
medicals, stock 50mM in DMSO). For acyl-carnitine measurements, the medium
was supplemented with 1mM L-carnitine (CAS 6645-46-1, Sigma-Aldrich, C0283).
Each experiment was performed in three biological repeats.
NMR spectroscopy. NMR experiments were performed on a 500-MHz Bruker
Avance spectrometer with a 5-mm TXI z-gradient probe (Bruker-BioSpin, Karls-
ruhe, Germany) at 298 K. 13C enrichments were determined by one-dimensional
1H NMR difference spectroscopy (13C-coupled spectrum minus the 13C-decou-
pled spectrum). Two-dimensional indirect-detected 13C, 1H J-resolved HSQC
spectra were recorded over an experimental time of 1.5 d per spectrum with 5,120
indirect 13C data points, at 80 p.p.m. 13C sweep width, 40 p.p.m. carrier position,
4,096 direct 1H increments, 3 s recycling delay and 8 scans. Before Fourier
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transformation, the data were multiplied with a squared sine-bell window function,
phase corrected and zero-ﬁlled to 8,192 data points, for indirect 13C sampling.
Mass spectrometry. Quantiﬁcation of organic acids was accomplished by gas
chromatography-mass spectrometry (ThermoFisher Trace GC Ultra/DSQ II single
quadrupole mass spectrometer). Calibration standards were prepared in water and
spiked with stable isotope-labelled internal standards. Detecting the derivatized
organic acids was achieved by single ion monitoring of each derivative after gas
chromatography separation. Acyl-carnitines were quantiﬁcated by LC/MS/MS
(Waters Ultra Performance LC/triple quadrupole mass spectrometer) using ﬂow
injection analysis with electrospray ionization. Calibration standards of the acyl-
carnitines were prepared in bovine serum spiked with stable isotope-labelled
internal standards. Parent ion scanning was used to detect parent, acyl-carnitine
molecular ions that produced a characteristic acyl-carnitine fragment ion,
m/z¼ 99, formed by collision-induced dissociation.
Enzymatic assays. Pyridoxal 50-phosphate or vitamin B6 was determined in an
enzymatic plasma assay (A/C Diagnostics, ACB6001), which we adapted to
quantify tissue culture supernatant or intracellular Vitamin B6 content by using
PBST buffer with 0.1% Tween-20 (CAS 9005-64-5, Sigma-Aldrich, P9416).
Additional methods for analysis of metformin response. Acyl-carnitine species
from 2 to 16 carbons and organic acids of the tricarboxylic acid cycle were
analysed by liquid chromatography mass spectrometry and show dose-dependent
associations upon metformin treatment in MCF-7 cells. Acetyl-carnitine (C2)
values were determined in nmolmg 1 protein (scaled by factor 1/1,000) and were
compared with acyl-carnitine (C12-C16) levels in pmolmg 1 protein. Organic
acids were determined in nmolmg 1 protein.
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